These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 15094232)

  • 1. HVR-1 quasispecies modifications occur early and are correlated to initial but not sustained response in HCV-infected patients treated with pegylated- or standard-interferon and ribavirin.
    Abbate I; Lo Iacono O; Di Stefano R; Cappiello G; Girardi E; Longo R; Ferraro D; Antonucci G; Di Marco V; Solmone M; Craxì A; Ippolito G; Capobianchi MR
    J Hepatol; 2004 May; 40(5):831-6. PubMed ID: 15094232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterogeneity of HVR-1 quasispecies is predictive of early but not sustained virological response in genotype 1b-infected patients undergoing combined treatment with PEG- or STD-IFN plus RBV.
    Abbate I; Cappiello G; Lo Iacono O; Longo R; Ferraro D; Antonucci G; Di Marco V; Di Stefano R; Craxì A; Solmone MC; Spanò A; Ippolito G; Capobianchi MR
    J Biol Regul Homeost Agents; 2003; 17(2):162-5. PubMed ID: 14518716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deep sequencing and phylogenetic analysis of variants resistant to interferon-based protease inhibitor therapy in chronic hepatitis induced by genotype 1b hepatitis C virus.
    Sato M; Maekawa S; Komatsu N; Tatsumi A; Miura M; Muraoka M; Suzuki Y; Amemiya F; Takano S; Fukasawa M; Nakayama Y; Yamaguchi T; Uetake T; Inoue T; Sato T; Sakamoto M; Yamashita A; Moriishi K; Enomoto N
    J Virol; 2015 Jun; 89(11):6105-16. PubMed ID: 25810555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load.
    Tsubota A; Arase Y; Someya T; Suzuki Y; Suzuki F; Saitoh S; Ikeda K; Akuta N; Hosaka T; Kobayashi M; Kumada H
    J Med Virol; 2005 Jan; 75(1):27-34. PubMed ID: 15543591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of different Peg-interferon alpha-2b regimens plus ribavirin in HCV-1b-infected patients after rapid virological response does not affect the achievement of sustained virological response.
    Napoli N; Giannelli G; Antonaci A; Antonaci S
    J Viral Hepat; 2008 Apr; 15(4):300-4. PubMed ID: 18307592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
    Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
    Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HVR-1 heterogeneity during treatment with telaprevir with or without pegylated interferon alfa-2a.
    Lange CM; Susser S; Herrmann E; Karey U; Kieffer TL; Kwong AD; Schinkel J; Reesink HW; Zeuzem S; Sarrazin C
    Scand J Gastroenterol; 2011 Nov; 46(11):1362-8. PubMed ID: 21815864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation between pre-treatment quasispecies complexity and treatment outcome in chronic HCV genotype 3a.
    Moreau I; Levis J; Crosbie O; Kenny-Walsh E; Fanning LJ
    Virol J; 2008 Jul; 5():78. PubMed ID: 18613968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variability of hepatitis C virus hypervariable region 1 (HVR-1) during the early phase of pegylated interferon and ribavirin therapy.
    Caraballo Cortés K; Laskus T; Bukowska-Ośko I; Pawełczyk A; Berak H; Horban A; Fic M; Radkowski M
    Adv Med Sci; 2012; 57(2):370-4. PubMed ID: 22968340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis C Virus p7 membrane protein quasispecies variability in chronically infected patients treated with interferon and ribavirin, with or without amantadine.
    Castelain S; Bonte D; Penin F; François C; Capron D; Dedeurwaerder S; Zawadzki P; Morel V; Wychowski C; Duverlie G
    J Med Virol; 2007 Feb; 79(2):144-54. PubMed ID: 17177298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic distance and heterogenecity between quasispecies is a critical predictor to IFN response in Egyptian patients with HCV genotype-4.
    Zekri AR; El-Din HM; Bahnassy AA; Khaled MM; Omar A; Fouad I; El-Hefnewi M; Thakeb F; El-Awady M
    Virol J; 2007 Feb; 4():16. PubMed ID: 17300723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quasispecies as predictive factor of rapid, early and sustained virological responses in chronic hepatitis C, genotype 1, treated with peginterferon-ribavirin.
    Salmerón J; Casado J; Rueda PM; Lafuente V; Diago M; Romero-Gómez M; Palacios A; León J; Gila A; Quiles R; Rodriguez L; Ruiz-Extremera A
    J Clin Virol; 2008 Apr; 41(4):264-9. PubMed ID: 18221912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C.
    Napoli N; Giannelli G; Parisi CV; Antonaci A; Maddalena G; Antonaci S
    New Microbiol; 2005 Jan; 28(1):13-21. PubMed ID: 15782622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quasispecies evolution in NS5A region of hepatitis C virus genotype 1b during interferon or combined interferon-ribavirin therapy.
    Veillon P; Payan C; Le Guillou-Guillemette H; Gaudy C; Lunel F
    World J Gastroenterol; 2007 Feb; 13(8):1195-203. PubMed ID: 17451199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quasispecies heterogeneity within the E1/E2 region as a pretreatment variable during pegylated interferon therapy of chronic hepatitis C virus infection.
    Chambers TJ; Fan X; Droll DA; Hembrador E; Slater T; Nickells MW; Dustin LB; Dibisceglie AM
    J Virol; 2005 Mar; 79(5):3071-83. PubMed ID: 15709027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pegylated interferon-alpha 2b-ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis.
    Derbala M; Amer A; Bener A; Lopez AC; Omar M; El Ghannam M
    J Viral Hepat; 2005 Jul; 12(4):380-5. PubMed ID: 15985008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia.
    Zeuzem S; Buti M; Ferenci P; Sperl J; Horsmans Y; Cianciara J; Ibranyi E; Weiland O; Noviello S; Brass C; Albrecht J
    J Hepatol; 2006 Jan; 44(1):97-103. PubMed ID: 16290907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of ribavirin on dynamics of hepatitis C viremia in interferon alpha-treated patiens with response or no response].
    Berg T; Kaul T; Naumann U; Wiedenmann B; Hopf U
    Z Gastroenterol; 2000 Nov; 38(11):881-6. PubMed ID: 11132533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response of hepatitis C genotype-4 naïve patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study.
    El-Zayadi AR; Attia M; Barakat EM; Badran HM; Hamdy H; El-Tawil A; El-Nakeeb A; Selim O; Saied A
    Am J Gastroenterol; 2005 Nov; 100(11):2447-52. PubMed ID: 16279899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART.
    Cargnel A; Angeli E; Mainini A; Gubertini G; Giorgi R; Schiavini M; Duca P;
    Antivir Ther; 2005; 10(2):309-17. PubMed ID: 15865225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.